Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | AXL | P30530 | 1/20 | 0.34 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.34 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.34 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL275155 | 0.95 | KMT2A (0.40) | KMT2AMEN1ALDH1A1TDP1AXL | |
| SCHEMBL6066165 | 0.92 | KMT2A (0.39) | KMT2AMEN1ALDH1A1TDP1AXL | |
| Phosphine SCHEMBL6066159 | 0.92 | KMT2A (0.39) | KMT2AMEN1ALDH1A1TDP1AXL | |
| SCHEMBL678617 | 0.84 | EGFR (0.36) | KMT2AMEN1ALDH1A1TDP1NFE2L2 | |
| SCHEMBL16019052 | 0.79 | MEN1 (0.33) | KMT2AMEN1ALDH1A1TDP1NFE2L2 | |
| SCHEMBL13946887 | 0.79 | ALDH1A1 (0.34) | KMT2AMEN1ALDH1A1TDP1NFE2L2 | |
| SCHEMBL6066125 | 0.79 | MEN1 (0.38) | KMT2AMEN1ALDH1A1TDP1KDM4E | |
| SCHEMBL6718662 | 0.74 | ALDH1A1 (0.42) | KMT2AMEN1ALDH1A1NFE2L2LMNA | |
| SCHEMBL8582433 | 0.74 | MEN1 (0.30) | KMT2AMEN1ALDH1A1TDP1 | |
| SCHEMBL1094509 | 0.74 | PDPK1 (0.34) | KMT2AMEN1ALDH1A1TDP1NFE2L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010523-A1 | Azaindazole compounds and methods of use | CHEMOCENTRYX, INC. (US) | 2007-01-11 | — | — | US | disclosed |
| WO-2007002667-A2 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010523-A1 | Azaindazole compounds and methods of use | CCR1, CCR3, CCR4 | KMT2A 3304/4885MEN1 4604/4885ALDH1A1 864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.